Shen Hong - Drug Metabolism and Pharmacokinetics Department, Bristol-Myers Squibb Company

基本信息

浏览量：15

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 90 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Pilot Study to Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants

Hong Shen,Runlan Huo,Yueping Zhang,Linna Wang, Nian Tong,Weiqi Chen, Andrew J Paris,Kofi Mensah, Min Chen,Yongjun Xue, Wenying Li,Michael Sinz

The Journal of pharmacology and experimental therapeuticsno. 2 (2024): 162-173

引用0浏览0WOS引用

Survey of Pharmaceutical Industry's Best Practices Around in Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group

DRUG METABOLISM AND DISPOSITIONno. 7 (2024): 582-596

引用0浏览0WOS引用

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

Matthew D. Harwood,Katharina Zettl,Manuel Weinheimer,Venkatesh Pilla-Reddy,Hong Shen, Frank Jacobs,Xiaoyan Chu,Felix Huth, Masanori Nakakariya,Paresh P. Chothe,Sibylle Neuhoff,Jacek R. Wisniewski

Molecular pharmaceuticsno. 7 (2023): 3505-3518

引用0浏览0WOS引用

Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease

Shawn Pei Feng Tan,Marie-Emilie Willemin,Jan Snoeys,Hong Shen,Amin Rostami-Hodjegan,Daniel Scotcher,Aleksandra Galetin

Clinical pharmacology and therapeutics/Clinical pharmacology & therapeuticsno. 6 (2023): 1243-1253

引用0浏览0WOS引用

Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry

Ryota Kikuchi,Paresh P. Chothe,Xiaoyan Chu,Felix Huth,Kazuya Ishida,Naoki Ishiguro,Rongrong Jiang,Hong Shen,Simone H. Stahl,Manthena V. S. Varma,Marie-Emilie Willemin,Bridget L. Morse

Clinical Pharmacology &amp Therapeuticsno. 6 (2023): 1170-1183

引用0浏览0WOS引用

Case study of OATP1B DDI assessment and challenges in drug discovery and development—real-life examples

Hong Shen,Jinping Gan,Giridhar Tirucherai

Elsevier eBookspp.189-199, (2023)

引用0浏览0引用

Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo

Yueping Zhang,Petia A. Shipkova,Bethanne M. Warrack,David M. Nelson,Linna Wang,Runlan Huo, Jian Chen,Erika Panfen,Xue-Qing Chen,R. Marcus Fancher, Qian Ruan,Lisa J. Christopher,Yongjun Xue,Michael Sinz,Hong Shen

Drug metabolism and disposition/DMD onlineno. 7 (2023): 851-861

引用0浏览0WOS引用

Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition

Sagnik Chatterjee, Anup Arunrao Deshpande,Hong Shen

Biopharm Drug Dispos（2023）

引用3浏览0WOS引用

Mechanistic Investigation of Liver Injury Induced by BMS-932481, an Experimental ɣ-Secretase Modulator

Xiaoliang Zhuo,Brett A Howell,Hong Shen,Jeffrey L Woodhead,Kathy Mosure,Yueping Zhang,Renato J Scialis,Ramaswamy Iyer,Yongnian Sun,Kenneth M Boy,Kimberly A Lentz,Rex Denton,Matthew G Soars,Benjamin M Johnson,W Griffith Humphreys

Toxicological sciences : an official journal of the Society of Toxicologyno. 2 (2023): 235-245

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn